Pancreatic Cancer Research

ResearcherNagoya City UniversityActive in the last 2 years

Yasuki Hori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9510-2568; OpenAlex author ID A5060894076. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Concomitant Pancreatic Ductal Adenocarcinoma and Type 1 Autoimmune Pancreatitis: A Potential Issue in the Diagnosis of Carcinoma by Endoscopic Ultrasound-guide… Co-author DOI 10.2169/internalmedicine.0075-22↗
  3. Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002032↗
  4. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer. Co-author DOI 10.1111/cas.14689↗
  5. Metachronous Pancreatic Ductal Adenocarcinoma with Adjacent Serous Cystadenoma that Was Preoperatively Diagnosed by EUS-FNA: A Case Report and Review of the Li… Co-author DOI 10.2169/internalmedicine.3912-19↗
  6. Case of pancreatic metastasis from colon cancer in which cell block using the Trefle® endoscopic scraper enables differential diagnosis from pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i3.91↗
  7. Maltotriose Conjugation to a Chlorin Derivative Enhances the Antitumor Effects of Photodynamic Therapy in Peritoneal Dissemination of Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-16-0670↗
  8. Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0118829↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Itaru Naitoh · 7 shared papers, 2015–2023 · strength 0.66
  2. Michihiro Yoshida · 7 shared papers, 2015–2023 · strength 0.66
  3. Akihisa Kato · 7 shared papers, 2015–2023 · strength 0.66
  4. Hiromi Kataoka · 5 shared papers, 2017–2023 · strength 0.55
  5. Satoru Takahashi · 5 shared papers, 2017–2023 · strength 0.50
  6. Kenta Kachi · 3 shared papers, 2020–2023 · strength 0.37
  7. Naruomi Jinno · 3 shared papers, 2018–2021 · strength 0.29
  8. Yoichi Matsuo · 2 shared papers, 2020–2023 · strength 0.25
  9. Takashi Joh · 3 shared papers, 2015–2018 · strength 0.17
  10. Kenji Notohara · 1 shared paper, 2023 · strength 0.15
  11. Kenta Saito · 1 shared paper, 2023 · strength 0.15
  12. Hiroyuki Kato · 1 shared paper, 2022 · strength 0.12
  13. Tadahisa Inoue · 1 shared paper, 2022 · strength 0.12
  14. Shuji Takiguchi · 1 shared paper, 2018 · strength 0.07
  15. Hiroyuki Kato · 1 shared paper, 2018 · strength 0.07
  16. Takashi Murakami · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.